| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
- Mast cell degranulation [1]
- Allergic inflammation-related cytokines (IL-4, TNF-α, IgE) [1] |
|---|---|
| ln Vitro |
- Alisol C 23-acetate exhibits anti-allergic activity by inhibiting mast cell degranulation. At concentrations of 10, 20, 40 μM, it dose-dependently inhibited histamine release from rat peritoneal mast cells stimulated by compound 48/80 by 28±3%, 52±4%, and 75±5%, respectively [1]
- It suppressed the production of allergic inflammation-related cytokines: 40 μM reduced IL-4 and TNF-α secretion from activated splenocytes by 62±4% and 58±3%, respectively [1] - It showed no significant cytotoxicity to mast cells or splenocytes at concentrations up to 40 μM, with cell viability maintained above 90% [1] |
| ln Vivo |
- In DNCB-induced atopic dermatitis (AD) mouse model: Oral administration of Alisol C 23-acetate (10, 20 mg/kg, daily for 21 days) dose-dependently alleviated AD-like symptoms. The skin severity score (erythema, edema, scaling) decreased by 35±3% (10 mg/kg) and 58±4% (20 mg/kg) compared to the model group [1]
- It reduced allergic inflammation in skin tissues: 20 mg/kg dose decreased the number of infiltrated inflammatory cells (e.g., eosinophils, lymphocytes) by 63±5%, and lowered skin tissue levels of IL-4, TNF-α, and IgE by 57±4%, 53±3%, and 48±3%, respectively [1] - It improved skin barrier function: 20 mg/kg increased skin hydration by 42±3% and reduced transepidermal water loss (TEWL) by 45±4% [1] |
| Cell Assay |
- Mast cell degranulation assay: Rat peritoneal mast cells were isolated and seeded in 96-well plates (1×10⁵ cells/well). Cells were pretreated with Alisol C 23-acetate (10–40 μM) for 1 hour, then stimulated with compound 48/80. Histamine levels in supernatants were measured by fluorometric assay [1]
- Cytokine secretion assay: Splenocytes were isolated from mice, cultured in 24-well plates (2×10⁶ cells/well), and activated with concanavalin A. Alisol C 23-acetate (10–40 μM) was added, and cells were incubated for 48 hours. IL-4 and TNF-α levels in supernatants were detected by ELISA [1] - Cytotoxicity assay: Mast cells and splenocytes were treated with Alisol C 23-acetate (10–40 μM) for 24 hours, and cell viability was measured by MTT assay [1] |
| Animal Protocol |
- DNCB-induced AD mouse model: Female BALB/c mice (6–8 weeks old) were sensitized with 2,4-dinitrochlorobenzene (DNCB) on the dorsal skin and ears. After sensitization, mice were randomly divided into model group and Alisol C 23-acetate groups (10, 20 mg/kg). The compound was dissolved in corn oil and administered orally once daily for 21 days. Skin severity score was evaluated weekly; skin hydration and TEWL were measured using a corneometer and tewameter, respectively [1]
- Tissue and biochemical analysis: Mice were sacrificed after 21 days. Skin tissues were collected for histological examination (hematoxylin-eosin staining) to count inflammatory cells; serum and skin homogenates were prepared to detect IL-4, TNF-α, and IgE levels by ELISA [1] |
| References | |
| Additional Infomation |
Alisol C 23-acetate is a triterpenoid compound.
It has been reported that Alisol C monoacetate is present in Alisma plantago-aquatica, and there are relevant data. See also: Alisma plantago-aquatica subsp. orientale root (part). - Alisol C 23-acetate is a triterpenoid derivative isolated from the rhizome of Alisma plantago-aquatica (a traditional Chinese medicine)[1]. - Its anti-allergic and anti-atopic dermatitis mechanisms include inhibiting mast cell degranulation, reducing the production of pro-inflammatory cytokines (IL-4, TNF-α) and regulating IgE levels to alleviate allergic inflammation[1]. - It has shown potential value in treating allergic diseases and atopic dermatitis, with good in vitro safety (no obvious cytotoxicity)[1]. |
| Molecular Formula |
C32H48O6
|
|---|---|
| Molecular Weight |
528.7199
|
| Exact Mass |
528.345
|
| Elemental Analysis |
C, 72.69; H, 9.15; O, 18.16
|
| CAS # |
26575-93-9
|
| PubChem CID |
14036813
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
624.9±55.0 °C at 760 mmHg
|
| Flash Point |
192.9±25.0 °C
|
| Vapour Pressure |
0.0±4.1 mmHg at 25°C
|
| Index of Refraction |
1.548
|
| LogP |
3.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1100
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O([H])[C@@]1([H])C([H])([H])C2=C([C@]([H])(C([H])([H])[H])C([H])([H])[C@@]([H])([C@]3([H])C(C([H])([H])[H])(C([H])([H])[H])O3)OC(C([H])([H])[H])=O)C(C([H])([H])[C@]2(C([H])([H])[H])[C@@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]3([H])C(C([H])([H])[H])(C([H])([H])[H])C(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@@]21[H])=O)=O
|
| InChi Key |
KOOCQNIPRJEMDH-QSKXMHMESA-N
|
| InChi Code |
InChI=1S/C32H48O6/c1-17(14-22(37-18(2)33)27-29(5,6)38-27)25-19-15-20(34)26-30(7)12-11-24(36)28(3,4)23(30)10-13-31(26,8)32(19,9)16-21(25)35/h17,20,22-23,26-27,34H,10-16H2,1-9H3/t17-,20+,22+,23+,26+,27-,30+,31+,32+/m1/s1
|
| Chemical Name |
[(1S,3R)-1-[(2R)-3,3-dimethyloxiran-2-yl]-3-[(5R,8S,9S,10S,11S,14R)-11-hydroxy-4,4,8,10,14-pentamethyl-3,16-dioxo-2,5,6,7,9,11,12,15-octahydro-1H-cyclopenta[a]phenanthren-17-yl]butyl] acetate
|
| Synonyms |
Alisol C 23acetate; Alisol C 23-acetate; AC23A; Alisol C 23 acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~47.28 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8914 mL | 9.4568 mL | 18.9136 mL | |
| 5 mM | 0.3783 mL | 1.8914 mL | 3.7827 mL | |
| 10 mM | 0.1891 mL | 0.9457 mL | 1.8914 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
